These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38801069)

  • 1. T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer.
    Palecki J; Bhasin A; Bernstein A; Mille PJ; Tester WJ; Kelly WK; Zarrabi KK
    Cancer Biol Ther; 2024 Dec; 25(1):2356820. PubMed ID: 38801069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
    Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
    Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells.
    Bühler P; Wolf P; Gierschner D; Schaber I; Katzenwadel A; Schultze-Seemann W; Wetterauer U; Tacke M; Swamy M; Schamel WW; Elsässer-Beile U
    Cancer Immunol Immunother; 2008 Jan; 57(1):43-52. PubMed ID: 17579857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous targeting of prostate stem cell antigen and prostate-specific membrane antigen improves the killing of prostate cancer cells using a novel modular T cell-retargeting system.
    Arndt C; Feldmann A; Koristka S; Cartellieri M; Dimmel M; Ehninger A; Ehninger G; Bachmann M
    Prostate; 2014 Sep; 74(13):1335-46. PubMed ID: 25053443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bispecific antibodies targeting CD3 in oncology and hematology].
    Vanacker H; Vinceneux A; Nicolas-Virelizier E; Brahmi M; Cassier PA
    Bull Cancer; 2021 Oct; 108(10S):S181-S194. PubMed ID: 34920802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer.
    Dorff TB; Narayan V; Forman SJ; Zang PD; Fraietta JA; June CH; Haas NB; Priceman SJ
    Clin Cancer Res; 2022 Feb; 28(4):576-584. PubMed ID: 34675084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
    Klinger M; Benjamin J; Kischel R; Stienen S; Zugmaier G
    Immunol Rev; 2016 Mar; 270(1):193-208. PubMed ID: 26864113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment.
    Yuraszeck T; Kasichayanula S; Benjamin JE
    Clin Pharmacol Ther; 2017 May; 101(5):634-645. PubMed ID: 28182247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation.
    Chiu D; Tavaré R; Haber L; Aina OH; Vazzana K; Ram P; Danton M; Finney J; Jalal S; Krueger P; Giurleo JT; Ma D; Smith E; Thurston G; Kirshner JR; Crawford A
    Cancer Immunol Res; 2020 May; 8(5):596-608. PubMed ID: 32184296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer.
    Stieglmaier J; Benjamin J; Nagorsen D
    Expert Opin Biol Ther; 2015; 15(8):1093-9. PubMed ID: 25971805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.
    Friedrich M; Raum T; Lutterbuese R; Voelkel M; Deegen P; Rau D; Kischel R; Hoffmann P; Brandl C; Schuhmacher J; Mueller P; Finnern R; Fuergut M; Zopf D; Slootstra JW; Baeuerle PA; Rattel B; Kufer P
    Mol Cancer Ther; 2012 Dec; 11(12):2664-73. PubMed ID: 23041545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies comparing different bispecific antibodies for redirecting T cell cytotoxicity to extracellular antigens on prostate carcinomas.
    Lum HE; Miller M; Davol PA; Grabert RC; Davis JB; Lum LG
    Anticancer Res; 2005; 25(1A):43-52. PubMed ID: 15816517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
    Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
    Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
    Einsele H; Borghaei H; Orlowski RZ; Subklewe M; Roboz GJ; Zugmaier G; Kufer P; Iskander K; Kantarjian HM
    Cancer; 2020 Jul; 126(14):3192-3201. PubMed ID: 32401342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer.
    Nolan-Stevaux O; Li C; Liang L; Zhan J; Estrada J; Osgood T; Li F; Zhang H; Case R; Murawsky CM; Estes B; Moore GL; Bernett MJ; Muchhal U; Desjarlais JR; Staley BK; Stevens J; Cooke KS; Aeffner F; Thomas O; Stieglmaier J; Lee JL; Coxon A; Bailis JM
    Cancer Discov; 2024 Jan; 14(1):90-103. PubMed ID: 37861452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
    Fournier P; Schirrmacher V
    BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Immunomodulatory Antibodies for Cancer Immunotherapy.
    Blanco B; Domínguez-Alonso C; Alvarez-Vallina L
    Clin Cancer Res; 2021 Oct; 27(20):5457-5464. PubMed ID: 34108185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.